12183267.txt 0 surveillance   antiviralagentresistant herpes simplex virus     general population   recurrent herpes labialis
12183267.txt 1     general population survey     united states   prevalence   antiviralagentresistant herpes simplex virus was very low among   than 1000 isolates   individuals   an episode   recurrent herpes labialis   treated   topical antiviral agents two isolates had borderline resistance   acyclovir 02     were susceptible   penciclovir
12183267.txt 2 
12183267.txt 3 between october 1998   february 1999   study was undertaken   10 states across   united states   determine   background prevalence   herpes simplex virus hsv resistant   acyclovir   penciclovir among isolates   subjects   an episode   recurrent herpes labialis rhl   had   been treated     topical antiviral agent results   other studies   immunocompetent patients   hsv infection have shown     prevalence   resistant virus   low    m reyes j graber n weatherall c hodgessavola w c reeves     task force   herpesvirus resistance 11th international conference   antiviral research april 1998 antivir res 37a44 abstract 1998   stable despite increasing rates   use   antiviral medication topical penciclovir cream was approved     food   drug administration   1996     prescription product     treatment   rhl topical acyclovir cream     treatment   rhl   available   many markets often without prescription   has   been approved   use     united states   survey formed part     program   support an application   switch penciclovir     prescription product     nonprescription product one   could   sold over   counter otc   was anticipated   approval   otc use   increase   levels   use   penciclovir   therefore any future change     prevalence   resistant virus could   tracked against   background prevalence established prior     switch   otc status     time   implementation   survey was sponsored jointly   two pharmaceutical companies   was planned   collaboration     task force   herpes simplex virus resistance these data were presented     thirteenth international conference   antiviral research baltimore md april 2000   study was conducted   accordance     clinical practice   received essex institutional review board approval pharmacists   47 communitybased pharmacies were responsible     clinical phase     study    subjects volunteered     study   response   advertisements placed     media  eligible subjects were aged 12 years   had perioral herpes labialis     vesicle   soft ulcer stage   topical treatment   an antiviral agent was permitted prior   completion     study although subjects who received any oral antiviral agent   hsv infection were   excluded efforts were made   identify individuals who may have been immunocompromised   asking subjects   complete one page     case report form   was   sealed   an envelope     subject   maintain confidentiality   subsequently transferred     data management team subjects responded   questions   medical history history   cancer human immunodeficiency virus infection hiv   aids   organ transplantation   completed   checklist   medications     were taking use     may have implied     subject was immunocompromised   checklist specified drugs   immunosuppressant activity   drugs used   treat hiv infection   aids   other diseases associated   defects     immune system   total   1803 subjects were recruited   each subject was swabbed once   study population n  1795 subjects   swabs processed   virus isolation was principally female 676     mean age   375 years standard deviation sd 1534 years caucasians formed   largest racial group 899   preponderance   female caucasians     study may reflect   sector     population     concerned about rhl        motivated   seek treatment    mean  sd number   episodes experienced during   previous 12 months was 52  526     mean age     first episode was 131 years   mean  sd duration   an episode   rhl was reported     81  48 days lesions were swabbed     pharmacist   swabs were stored   transport medium   4c   shipped     central laboratory within 3   4 days virus was isolated   primary rabbit kidney cells    cell suspension prepared   each infected culture was used   type   virus   indirect immunofluorescence vero cells   mrc5 cells were used     plaque reduction assays   acyclovir   penciclovir respectively monolayers   sixwell plates were infected   50   100 pfu per well after adsorption   inoculum was removed   replaced   culture medium containing methylcellulose 2     test antiviral agent final concentrations 0   30 mugml tested   duplicate after incubation   3 days   36  1c   5   7 co2   monolayers were fixed   stained   plaques were counted     50 inhibitory concentrations ic50s were calculated two standard hsv type 1 hsv1 reference strains were included     assays sc16     sensitive   acyclovir   penciclovir   dm21   thymidine kinasenegative mutant     resistant   acyclovir   penciclovir summary ic50 data   these strains   provided   table  table 1  summary   hsv1 susceptibility   acyclovir   penciclovir   antiviral use   medical history   1803 cultures yielded 1087 isolates       were typed   hsv1   total   1002 isolates were tested   their susceptibilities   acyclovir   penciclovir   2 additional isolates were also tested   their susceptibilities   penciclovir   breakpoint   defining resistance   acyclovir was an ic50 2 mugml  two criteria were applied   define penciclovir resistance   an ic50 2 mugml   ii an ic50 three     times greater than   mean ic50   penciclovir     isolates     survey 084 mugml two hsv1 isolates were confirmed     resistant   acyclovir ic50s 321   241 mugml respectively   resistance was borderline     assay       original assay ic50s 221   435 mugml respectively both isolates were sensitive   penciclovir ic50s 038   034 mugml respectively   two subjects   acyclovirresistant hsv1 isolates were immunocompetent one subject had   history   antiviral agent use     other subject reported prior use   acyclovir   during   episode evaluated     present study   other isolates were susceptible   acyclovir therefore   prevalence   acyclovirresistant hsv1 isolates was 020 2   1002 isolates tested 95 confidence interval 002   072   total   1004 hsv1 isolates were tested   their susceptibilities   penciclovir   none was found     resistant 0   1004 isolates tested prevalence 000 95 confidence interval 000   037 these results   consistent   data     similar survey conducted     united kingdom     time when topical acyclovir had been available otc   5 years   topical penciclovir had been available     prescription medicine   2 years  one resistant hsv1 isolate   was cross resistant   acyclovir   penciclovir was identified 1   924 isolates tested   susceptibility   acyclovir 1   915 isolates tested   susceptibility   penciclovir prevalence 01  other surveys   immunocompetent populations predominantly patients   genital herpes have reported   prevalence   hsv resistance   01   07   reyes et al antivir res 37a44 abstract 1998   historical prevalence   acyclovirresistant hsv isolates among untreated immunocompetent patients   measured     plaque reduction assay   03  resistant hsv     common   immunocompromised patients   example     surveillance study   reyes et al reyes et al antivir res 37a44 abstract 1998 4   62 65 isolates   hivinfected patients were resistant   acyclovir ic50 data     present survey were analyzed   investigate differences     susceptibilities   isolates     study subjects   acyclovir   penciclovir     basis   their reported use   antiviral agents immunocompetence   history   rhl    isolates   subjects who reported use   antiviral medication   treat herpesvirus infections   median ic50 was similar     median ic50   isolates   subjects who had never used antiviral medication both   acyclovir p  0211     penciclovir p  0649     small number   isolates n  49   subjects who used oral acyclovir famciclovir   valacyclovir     time     study   median ic50   acyclovir 031 mugml was significantly lower than     isolates   subjects who were   using antiviral medication 043 mugml p  0025   difference     clinically important   may simply have arisen   chance   parallel comparison   penciclovir showed   significant difference p  0488   other comparisons reached statistical significance including     immune status although   number   subjects     survey who may have been immunocompromised was low    conclusion   prevalence   resistant hsv1 strains among isolates     general population   rhl   low consistent   earlier surveys   immunocompetent patients   hsv infection despite   increasing rate   use   herpesvirusspecific antiviral agents over   past two decades
12183267.txt 4 
